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Abstract
Background: Development of a standardized platform for the rapid expansion of tumor-infiltrating lymphocytes
(TILs) with anti-tumor function from patients with limited TIL numbers or tumor tissues challenges their clinical
application.
Methods: To facilitate adoptive immunotherapy, we applied genetically-engineered K562 cell-based artificial
antigen presenting cells (aAPCs) for the direct and rapid expansion of TILs isolated from primary cancer specimens.
Results: TILs outgrown in IL-2 undergo rapid, CD28-independent expansion in response to aAPC stimulation that
requires provision of exogenous IL-2 cytokine support. aAPCs induce numerical expansion of TILs that is statistically
similar to an established rapid expansion method at a 100-fold lower feeder cell to TIL ratio, and greater than
those achievable using anti-CD3/CD28 activation beads or extended IL-2 culture. aAPC-expanded TILs undergo
numerical expansion of tumor antigen-specific cells, remain amenable to secondary aAPC-based expansion, and
have low CD4/CD8 ratios and FOXP3+ CD4+ cell frequencies. TILs can also be expanded directly from fresh
enzyme-digested tumor specimens when pulsed with aAPCs. These “young” TILs are tumor-reactive, positively
skewed in CD8+ lymphocyte composition, CD28 and CD27 expression, and contain fewer FOXP3+ T cells
compared to parallel IL-2 cultures.
Conclusion: Genetically-enhanced aAPCs represent a standardized, “off-the-shelf” platform for the direct ex vivo
expansion of TILs of suitable number, phenotype and function for use in adoptive immunotherapy.
Introduction
Adoptive immunotherapy using tumor-reactive T lym-
phocytes has emerged as a powerful approach for the
treatment of bulky, refractory cancer [1], however the
ability to generate large numbers of TILs for therapy is a
challenge that has significant regulatory hurdles, and
requires technically sophisticated cell processing and
extended in vitro lymphocyte culturing periods. Long-
term culture of tumor-derived T cells in high-dose inter-
leukin-2 (IL-2) allows for the generation of high numbers
of TILs (>1 × 10
11) but with preferential expansion of
CD4+ lymphocytes [2-4]. Initial IL-2-based TIL
expansion followed by a “rapid expansion method”
(REM) [5-9] is a more time and labor efficient method,
requiring an excess of irradiated allogeneic peripheral
blood mononuclear cells (PBMC) as feeder cells, anti-
CD3 antibody and high doses of IL-2, that can result in
a 1,000-fold expansion of TILs over a 14-day period [9].
While routinely used, the REM has introduced technical,
regulatory, and logistic challenges that have prevented
larger and randomized clinical trials as a prelude to
widespread application. First, large numbers of allogeneic
feeders (200-fold excess), often from multiple donors, are
required for clinical expansions. Second, allogeneic feeder
cells harvested by large-volume leukapheresis from
healthy donors exhibit donor to donor variability in their
viability after cryopreservation and capacity to support
TIL expansion, and thus test expansions are often
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extensive and costly laboratory testing of each individual
donor cell product to confirm sterility.
Artificial antigen presenting cells (aAPCs) expressing
ligands for the T cell receptor and costimulatory mole-
cules can activate and expand T cells for transfer, while
improving their potency and function. The first genera-
tion of aAPC consisted of anti-CD3 and anti-CD28
monoclonal antibodies (mAbs) covalently bound to
magnetic beads (CD3/CD28 beads) which crosslink CD3
and CD28 on T cells, enabling efficient polyclonal
expansion of circulating T cells (50 to 1000-fold) over
10-14 days of ex vivo culture with preferential expansion
of naïve and memory CD4+ T cells [10], however their
efficiency in TIL expansion has not been examined.
Second generation cell-based aAPCs can substitute for
natural APCs, mediate efficient expansion of antigen-
specific T cells from peripheral blood [11-16] and stably
express multiple gene inserts, including CD64 (the high-
affinity Fc receptor), CD32 (the low-affinity Fc receptor),
and CD137L (4-1BBL), among others [13,15]. Compared
to beads, cell-based aAPCs bearing the costimulatory
ligand CD137L can more efficiently induce the prolifera-
tion of antigen-experienced CD8+ CD28
- Tc e l l sf r o m
peripheral blood and improve their in vivo persistence
and antitumor activity upon adoptive transfer to tumor-
bearing mice [15,17]. In these studies, enhanced prolif-
eration of antigen-experienced CD8+ CD28
- T cells
mediated by aAPCs is dependent on CD137 ligation
[15,17].
Unlike peripheral blood lymphocytes (PBL), most tumor
antigen-specific CD8+ TILs d e r i v e df r o ms o l i dt u m o r s
express low levels of CD28 [18,19]. Together, the above
studies suggest that approaches utilizing CD137 ligation
may support ex vivo TIL expansion. In a trial of adoptive
TIL transfer with REM generated cells, the persistence of
TILs in vivo after infusion represented a major limitation
to successful therapy [20]. In vivo persistence and clinical
response were both associated with expression of the cost-
imulatory molecules CD28 and CD27 by TILs, as well as
their telomere length [18,21-24]. The REM requires
extended duration TIL culture which results in telomere
length shortening and reduced expression of CD28 and
CD27 [18,25], thus there remains a need for the develop-
ment of improved, standardized methods and materials
for generating TILs rapidly for adoptive transfer with
greater potency and engraftment capability.
Here we investigate the use of engineered K562 cell-
based aAPCs as an “off-the-shelf” platform for ex vivo
TIL expansion. K562 aAPCs that express CD137L offer
the potential to expand antigen-experienced TILs and
represent a potential new cell-based platform for the
standardization of ex vivo TIL expansion. Ovarian can-
cer and melanoma biospecimens were used to test the
notion that aAPC can stimulate TIL expansion in differ-
ent tumor histotypes [26,27], based on the knowledge
that TILs from these cancers can recognize autologous
tumor as well as known tumor antigens in vitro [28-32],
and exhibit tumor-specific reactivity ex vivo [33,34] and
in vivo [5,7,35]. We found that aAPCs efficiently expand
IL-2 cultured TILs from solid tumor specimens of ovar-
ian cancer similar to the REM, resulting in a favorable
CD4/8 T cell ratio, and low FOXP3+ CD4 T cell com-
position. aAPC-based TIL expansion depends on the
provision of exogenous IL-2 cytokine support in culture
and is largely CD28-independent. Under these condi-
tions, tumor antigen-specific TILs with demonstrated
anti-tumor reactivity can be expanded. Further, aAPC
can induce the rapid and efficient expansion of TILs
directly from freshly digested tumor samples, reducing
overall culture time, and output TILs are highly skewed
in CD8+ lymphocyte composition, possess high levels of
CD28 and CD27 expression after activation and are
amenable to secondary aAPC-based expansion. The
aAPC platform as described here thus establishes a stan-
dardized methodology for the rapid, clinical-grade
expansion of TILs for therapy.
Materials and methods
Generation of TILs
Patients were entered into an Institutional Review
Board-approved clinical protocol and signed an
informed consent prior to initiation of lymphocyte cul-
tures. Generation of TILs was performed as described
elsewhere [9]. Briefly, 2 mm
3 tumor fragments were cul-
tured in complete media (CM) comprised of AIM-V
medium (Invitrogen Life Technologies, Carlsbad, CA)
supplemented with 2 mM glutamine (Mediatech, Inc.
Manassas, VA), 100 U/ml penicillin (Invitrogen Life
Technologies), 100 μg/ml streptomycin (Invitrogen Life
Technologies), 5% heat-inactivated human AB serum
(Valley Biomedical, Inc. Winchester, VA) and 600 IU/
mL rhIL-2 (Chiron, Emeryville, CA). TILs established
from fragments were grown for 3-4 weeks in CM and
expanded fresh or cryopreserved in heat-inactivated
HAB serum with 10% DMSO and stored at -180°C until
the time of study. Tumor associated lymphocytes (TAL)
obtained from ascites collections were seeded at 3e6
cells/well of a 24 well plate in CM. TIL growth was
inspected about every other day using a low-power
inverted microscope. Each initial well was considered to
be an independent TIL culture and was maintained
accordingly. For enzymatic digestion of solid tumors,
tumor specimen was diced into RPMI-1640, washed and
centrifuged at 800 rpm for 5 minutes at 15-22°C, and
resuspended in enzymatic digestion buffer (0.2 mg/ml
Collagenase and 30 units/ml of DNase in RPMI-1640)
followed by overnight rotation at room temperature.
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KT64/BBL and KT32/BBL aAPCs were generated, cul-
tured and prepared for co-culture as previously
described [13,15]. Briefly, Fc-binding receptors on
KT64/BBL aAPCs were pre-cleared of serum immuno-
globulins by culture in serum free AIM-V medium
(SFM) overnight and then irradiated at 10,000 rad. Anti-
CD3 (OKT-3) with or without anti-CD28 (clone 9.3)
mAbs were loaded on aAPCs at 0.5 ug/10
6 cells at 4°C
f o r3 0m i n u t e s .B e f o r eu s e ,a A P C sw e r ew a s h e dt w i c e
with SFM. For KT32/BBL aAPCs, anti-CD3 and anti-
CD28 antibodies were not washed out of culture med-
ium, per established protocol [13,15]. For expansion of
IL-2 cultured TILs, an optimal 2:1 aAPC to TIL ratio
was established and used in all experiments.
Expansion of TILs and TALs in vitro using aAPCs
10
6 heterogonous TILs or TALs were co-cultured with
KT64/BBL or KT32/BBL aAPCs loaded with anti-CD3
with or without anti-CD28 antibody in one well of a 24
well plate. rhIL-2 (100 IU/ml) was added into co-cultures
at day 2. Every other day the cell number was counted by
on a Coulter Multisizer and adjusted to a concentration of
0.5-1 × 10
6 cells/ml until day 8. Expanding cocultures
were transferred into an appropriately sized flask and sus-
pended in CM containing rhIL-2 100 IU/ml depending on
total cell numbers. Confirmatory hemacytometer counts
including Trypan Blue exclusion were performed. After
day 9, phenotypes of expanded TILs or TALs were exam-
ined by flow cytometry. Final expanded products were uni-
formly comprised by CD3+ TILs, TALs or PBLs, without
aAPC contamination, as verified by cell sizing, morphology
and flow cytometry. The total duration of cell expansion
culture was between 9 and 14 days. At the end of culture,
all remaining cells were frozen in 90% HAB serum and
10% DMSO for continued analysis. For comparison to
other methods of T cell expansion, TILs or TALs were
cultured in three conditions: with rhIL-2 (600 IU/ml) in
CM; with anti-CD3/CD28 magnetic beads (3:1 beads to T
cells) in rhIL-2 (100 IU/ml) (Chiron); or in a “rapid expan-
sion method” condition (200:1 allogeneic PBMC:TILs,
30 ng/ml of OKT-3 anti-CD3 mAb and 6000 IU/ml rhIL-
2 in 20 mL of CM in a T75 flask). For stimulation of fresh
tumor digests, 10
6 total cells from tumor digested pro-
ducts were stimulated using an equivalent number of irra-
diated aAPC loaded with anti-CD3 mAb in media
supplemented with 100 IU/mL IL-2.
Antibodies and flow cytometric immunofluorescence
analysis
Antibodies against human CD3, CD4, CD8, CD16,
CD25, CD32, CD64 and CD137 were purchased from
BD Bioscience. 7-AAD antibody for viability staining
was purchased from BD Bioscience (San Jose, CA).
HER2:369-377 peptide (KIFGSLAFL) and MART-1:26-
35(27L) peptide (ELAGIGILTV) containing HLA-A2010
tetramers were purchased from Beckman Coulter, Inc.
(Brea, CA). Anti-FOXP3 antibody (clone 259D) was
obtained from BioLegend (San Diego, CA). Fresh TILs
or TALs were resuspended in FACS buffer consisting of
PBS with 2% FBS (Gemini Bioproducts) at 10
7 cells/ml
and blocked with 10% normal mouse Ig (Caltag Labora-
tories) for 10 min on ice. A total of 10
6 cells in 100 μl
were stained with fluoro-chrome-conjugated mAbs at
4°C for 40 min in the dark. In some cases, cells were
briefly stained with 7-AAD antibody for nonviable cell
exclusion after washing twice and subsequently analyzed
in a FACSCanto II (BD Biosciences). FOXP3 staining
was performed using the eBioscience fixation and per-
meablization kits according to the manufacturer’s
instructions and cells stained with the anti-FOXP3 anti-
body from BioLegend. K562 aAPCs antibody loading
was performed using anti-CD3 (OKT3) purchased from
eBioscience (San Diego, CA) and anti-CD28 mAbs
(clone 9.3). For cell division assays, TILs or PBLs were
labeled with 128 nM of carboxyfluorescein succinimidyl
ester (CFSE). CFSE labeled TILs or PBLs were expanded
with aAPCs, CD3/28 beads, rhIL-2 (600 IU/ml) or REM
as described above. At day 6, the cells were stained with
anti-CD3, anti-CD4 and anti-CD8 and examined for
CFSE division by FACS. Statistical significance of phe-
notypic differences was determined using paired two-
tailed T-test.
ELISA assay for T cell function
Stimulation of TILs by tumor cells was assessed by IFN-
g secretion. 1 × 10
5 TILs were cultured with 1 × 10
5 tar-
get cells in triplicate overnight in a 96 well U bottom
plate in 200 uL of CM containing 5% heat-inactivated
human AB serum. Supernatants were harvested and
analyzed for IFN-g by ELISA, according to manufac-
turer’s instruction (Biolegend, San Diego, CA). Values
represent the mean cytokine concentration (pg/mL) ±
SD of triplicate wells.
Results
KT64/BBL aAPCs-based expansion TILs
K562 cells expressing CD64, CD137L and CD28 ligands
CD80 and CD86, pulsed with anti-CD3 antibody effi-
ciently activate and expand CD8+ CD28- T cells and
antigen-specific T cells from peripheral blood when co-
cultured at a 0.5:1 aAPC to T cell ratio in the absence
of exogenous IL-2 and in a CD137L dependent manner
[15]. We therefore hypothesized that tumor infiltrating
lymphocytes (TILs) derived from cancer lesions could
be efficiently expanded to therapeutic treatment num-
bers using a K562 cell-based aAPC platform. To gener-
ate cell-based aAPCs, the parental K562 cell line was
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receptor CD64 and the costimulatory ligand CD137L
(4-1BBL) by lentiviral gene transduction. Single cell
clones (referred to as KT64/BBL) were isolated by flow-
sorting and their CD64 and CD137L surface expression
was confirmed by flow cytometry (Additional file 1Fig-
ure S1a). KT64/BBL aAPCs were cultured in the
absence of serum to pre-clear CD64 of serum derived
immunoglobulins, irradiated and then loaded with anti-
CD3 and anti-CD28 agonist monoclonal antibodies
(mAbs) for TIL expansion.
TIL cultures for expansion were outgrown from solid
ovarian cancer fragments for 3-4 weeks in culture media
(CM) containing 600 IU/mL rhIL-2 cytokine, as
described [4,9], and were comprised of >95% CD3+
T cells and <1.5% NK cells. To test the capacity of anti-
body-loaded aAPCs to mediate ex vivo expansion of
TILs, aAPC were co-cultured with TILs at aAPC to TIL
ratios ranging between 0.5 and 10 to 1 in the continued
presence of IL-2 (100 IU/ml). Peak TIL expansion was
achieved at the 2:1 aAPC to T cell ratio (Figure 1a),
which contrasts the 200:1 feeder to T cell ratio com-
monly used in REM-based TIL expansion [9]. The 2:1
aAPC to T cell ratio was therefore used for the experi-
ments detailed below. The contribution of CD137L to
TIL expansion was confirmed using control KT64
aAPCs lacking CD137L expression, which mediated
diminished TIL expansion compared to KT64/BBL
(Additional file 1Figure S1a,b), consistent with our
prior study using antigen-experienced T cells [15]. Since
our first generation of K562 based aAPC (referred to as
KT32/BBL) relied upon the low affinity Fc receptor
CD32 for anti-CD3 antibody loading and demonstrated
the capacity to expand circulating T cells [15], we evalu-
ated the relative efficiency of CD32 and CD64-expres-
sing aAPCs for expanding TILs. KT64/BBL aAPCs were
superior to KT32/BBL aAPCs, and therefore used in all
further experiments (Additional file 2Figure S2).
Robust expansion of TILs is dependent upon IL-2, but not
CD28 costimulation
To investigate the impact of CD28 costimulation and
IL-2 on aAPC-mediated TIL expansion, KT64/BBL
aAPCs were loaded with anti-CD3 mAb +/- anti-CD28
mAb and used to stimulate TILs in the presence or
absence of 100 IU/ml of IL-2 (Figure 1b). In the absence
of IL-2, TILs underwent minimal expansion after stimu-
lation with aAPCs loaded with anti-CD3 mAb with
(11-fold) or without anti-CD28 mAb (9-fold), albeit
more than when continually grown in IL-2 (3-fold). By
comparison, addition of IL-2 to aAPC-based expansion
induced vigorous numerical growth of TILs (>170-fold)
in the presence or absence of anti-CD28 mAb, and the
level of TIL expansion was similar whether or not anti-
CD28 mAb was loaded onto the aAPCs. These results
demonstrate that cell-based aAPC-mediated TIL expan-
sion is largely independent of CD28 signaling when
4-1BBL is provided on aAPC, but dramatically improved
by addition of IL-2 cytokine to culture.
The limited contribution provided by anti-CD28 mAb
to the expansion of TILs in the absence of IL-2 counters
that previously observed for peripheral blood T lympho-
cytes (PBLs) from healthy donors where CD28 costimu-
lation in concert with TCR signaling induces robust
proliferation [13,15]. We therefore evaluated the contri-
bution of CD28 in the expansion of TILs and PBLs col-
lected from the same patient with ovarian cancer. In
paired comparison, measurement of CD28 expression
on matched TILs and PBLs from the same patients
revealed a higher relative expression of surface CD28 by
T cells from the circulation than by T cells from tumor
in all cases (Additional file 3Figure S3). Among CD3+
TILs, more CD4+ TILs expressed CD28 than CD8+
TILs (76.5 ± 32.9% vs. 34.7 ± 12.2%, respectively; p =
0.003). CD3+ T cells from the blood were heteroge-
neous in differentiation state and comprised of naïve
(CD45RO- CD62L+), central memory (CD45RO+
CD62L+), and effector memory (CD45RO+ CD62L-)
cell subsets; TILs however were comprised primarily of
cells with a more differentiated, effector memory pheno-
type (representative examples are shown in Additional
file 3Figure S3).
Consistent with their disparate differentiation pheno-
types, peripheral blood T cells and TILs from the same
patient demonstrated a relative difference in expansion
in response to aAPC stimulation. The expansion of TILs
in response to stimulation with aAPCs loaded with anti-
CD3 mAb with or without CD28 agonist mAb co-load-
ing was modest and similar (62-fold v. 63-fold, respec-
tively), but was substantially augmented by the addition
of IL-2 to culture (182-fold; Figure 1c). PBLs in parallel
culture exhibited greater expansion in response to anti-
CD3 mAb loaded aAPC stimulation compared to TIL,
whether or not CD28 signaling was intact, however, PBL
expansion was substantially elevated when the aAPCs
were also loaded with CD28 agonist mAb (254-fold),
relative to anti-CD3 mAb alone (95-fold). In the absence
of CD28 costimulation, robust PBL expansion could be
restored by addition of exogenous IL-2 cytokine (187-
fold). Although PBL expansion in the condition of CD28
costimulation out-performed the addition of IL-2 at day
9 (Figure 1c), IL-2 supplementation was superior to
CD28 costimulation by day 11 of PBL culture (737-fold
v. 340-fold, respectively); at this time point, TIL cultures
were unchanged in expansion hierarchy with a 287-fold
e x p a n s i o ni nt h eC D 3 / I L - 2c o ndition. Consistent with
previous findings[15], PBLs stimulated with anti-CD3
and anti-CD28 mAb loaded aAPCs expanded better
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anti-CD3 and CD28 mAbs to crosslink endogenous
CD3 and CD28 (254-fold v. 56-fold, respectively; Figure
1c). TILs stimulated with CD3/CD28 beads did not
undergo robust expansion (18-fold).
Supplement of TIL cultures with IL-2 cytokine, but
not CD28 costimulation, during aAPC-induced stimula-
tion dramatically improved TIL expansion, while PBLs
showed improved expansion in response to aAPC with
addition of either IL-2 or CD28 costimulation. This sug-
gests that PBLs, which express elevated levels of CD28
relative to TILs, may produce and secrete more IL-2
when costimulated than their CD28
low TIL counterparts,
thus supporting T cell expansion. Consistent with this
notion, cytokine secretion analysis performed on super-
natants from TILs or PBLs stimulated overnight with
anti-CD3 mAb loaded aAPCs +/- anti-CD28 mAb
revealed that TILs produce little to no IL-2 when stimu-
lated with aAPC either with or without CD28 costimula-
tion, or with CD3/CD28 beads (Figure 1d). By contrast,
PBLs secreted high levels of IL-2 in response to aAPC
which was augmented by the addition of CD28 agonist
mAb loading. CD3/CD28 bead stimulation of PBLs
resulted in an even greater level of IL-2 production than
that achieved with aAPC. Both TILs and PBL secreted
IFN-g and TNF-a in response to aAPC and bead stimu-
lation (not shown), indicating that the lack of IL-2 pro-
duction by TILs was not a result of functional anergy.
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Figure 1 KT64/BBL aAPCs support the expansion of TILs in a CD28-independent manner.( a) TILs cultures established for 3-4 weeks in 600
IU/ml IL-2 were expanded using aAPCs loaded with anti-CD3 and anti-CD28 mAbs at various aAPC to T cell ratios in the continued presence of
IL-2 (100 IU/mL). In this representative experiment (one of three), a 62-fold expansion of TILs was achieved 9 days after a single stimulation with
aAPCs at the 2:1 aAPC to T cell ratio. A 3-fold expansion occurred after continued culture in IL-2. TILs stimulated with aAPCs underwent greater
expansion at all aAPC to TIL ratios compared to continued growth in IL-2 or growth in medium alone. (b) KT64/BBL aAPC-based TIL expansion is
CD28 costimulation-independent but augmented by provision of IL-2 support. Established TIL cultures were expanded for 9 days using aAPC
loaded with anti-CD3 antibody in the presence or absence of clone 9.3 anti-CD28 antibody, in the presence or absence of IL-2 supplement. (c)
CD28 costimulation augments the aAPC-based expansion of peripheral blood T cells, but not autologous TILs. CD3/28 beads do not support TIL
expansion (3:1 bead to T cell ratio). Day 9 cell counts are shown. (d) TILs stimulated with KT64/BBL aAPCs with or without anti-CD28 antibody
do not secrete IL-2 after overnight culture, but peripheral blood lymphocytes do. IL-2 secretion by PBL is increased by provision of CD28
costimulation and supported by CD3/28 bead stimulation. Mean IL-2 (pg/mL) concentration ± SEM from three independent TIL cultures is
shown.
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for TILs
To date, clinical preparation of TILs has largely relied
upon expansion by IL-2 alone [4,36] and, more recently,
by the “rapid expansion method” (REM) of anti-CD3
antibody, allogeneic feeder cells and IL-2 [5,8,9]. For
polyclonal expansion of peripheral blood T lymphocytes,
CD3/CD28 beads have been used [10], however their
application for TIL expansion has not been reported. We
compared the relative effectiveness of KT64/BBL aAPCs
and other established culture methods of TIL expansion.
TIL cultures outgrown in IL-2 containing CM and pri-
mary PBLs were either continually cultured in 600 IU/
mL IL-2, or activated with CD3/CD28 beads, REM or
KT64/BBL aAPCs. PBLs that were cultured in the pre-
sence of IL-2 did not divide, but underwent significant
cell division in response to CD3/CD28 beads, although a
fraction of cells remained undivided (Figure 2a). CD3/
CD28 bead-induced cell division by PBLs was suboptimal
and similar in level to that observed after activation with
KT64/BBL aAPCs loaded anti-CD3 mAb at the 0.5:1
aAPC to T cell ratio. By comparison, all PBLs divided
extensively after stimulation with aAPCs at aAPC to
T cell ratios of 2:1 and 5:1, or after expansion by REM.
In contrast to PBLs, a portion of TILs underwent IL-2
induced cell division, likely due to their pre-conditioning
in IL-2; however a substantial number of TILs in these
cultures did not divide. TILs cultured with aAPCs at the
2:1 ratio underwent extensive cell division, which was
similar to that observed in TILs stimulated by the REM,
and consistent with T cell counts (Figure 2a). Nearly all
TILs stimulated with CD3/CD28 beads or aAPCs at the
0.5:1 ratio divided, albeit at a moderate level. At the 5:1
ratio, most TILs had undergone an intermediate level of
cell division, consistent with cell counts (Figure 1b),
likely resulting from overcrowding due to space limita-
tions in culture vessels. After 9 days of culture, TILs sti-
mulated by REM or KT64/BBL aAPCs had undergone
significant cell expansion, relative to continued IL-2 cul-
ture (p < 0.05 by paired t-test; Figure 2b). TILs under-
went a mean fold expansion of 205 ± 77 (mean ± SEM)
when stimulated with the REM, and a 114 ± 54 fold-
expansion by aAPC, a difference which was not statisti-
cally significant (p = 0.15). Expansion of TILs with
CD3/CD28 beads was not robust, resulting in an 18.8 ±
7.3 mean fold expansion, and was not significantly dif-
ferent from continuous IL-2 culture (21.8 ± 11.9-fold, p
= 0.32) or media alone control (4.8 ± 2.2-fold; p = 0.12).
To evaluate their continued expansion potential, TILs
t h a th a de x p a n d e dl e s st h a n1 0 0 - f o l da f t e ras i n g l e -
round of aAPC stimulation were restimulated with
aAPC. After restimulation, TILs underwent further
robust expansion, reaching 10,000-fold growth over
25 days (Figure 2c).
TIL phenotype following aAPC expansion
Flow cytometric analysis was performed to determine
the impact of expansion by the various methods on TIL
phenotype. Prior to stimulation, CD4 T cells dominated
TIL cultures at a CD4: CD8 ratio of 2.05 ± 0.30 (mean
± SEM; n = 6). After expansion, aAPC stimulated TILs
had a low CD4:CD8 T cell ratio (0.77 ± 0.21) that was
statistically similar to that observed after REM or IL-2
based expansion (Figure 3a). TILs stimulated with CD3/
CD28 beads were largely comprised of CD4 T cells with
a CD4:CD8 ratio that was higher than those observed in
all other conditions (p < 0.04), likely due to the CD8+
TIL subset containing a much higher proportion of
CD28- cells than the CD4+ subset. Although a favorable
CD4:CD8 ratio (<1) was seen at the 2:1 aAPC:TIL ratio,
higher aAPC:TIL ratios resulted in increased CD4:CD8
ratios following stimulationa n dc u l t u r e( F i g u r e3 b ) .
CD16+ NK cells, which were detectable at levels <1.5%
of starting IL-2 cultured TIL samples, were not detect-
able after aAPC-based expansion (not shown). Among
CD4+ T cells in TIL cultures, the frequency of FOXP3+
CD4+ T cells was highest in TILs that had been
expanded with CD3/CD28 beads, which was signifi-
cantly greater than in TILs expanded with aAPC (p <
0.05; Figure 3c). Since in vitro activation of T cells can
induce transient FOXP3 upregulation [37], analysis was
performed only after TILs had rested down as defined
by a return of cells to their pre-expansion size, mea-
sured using a Multisizer 3 Cell Sizing device, and a lack
of spontaneous proinflammaorty cytokine release. The
level of FOXP3+ CD4+ T cells was similar among TILs
expanded with aAPC, REM or continuous IL-2 culture.
The differentiation phenotype of TILs after expansion
was not significantly different when stimulated with
KT64/BBL, beads, REM or IL-2 with a predominant
CD28
int CD27
low CD45RA
neg CD45RO
pos CCR7
low
CD62L
int phenotype (not shown).
Maintenance of tumor antigen-specific T cells after
aAPC-based expansion
TILs outgrown from ovarian cancer can recognize and
respond to stimulation with autologous tumor as well
as known tumor antigens ex vivo [28-34], although the
prevalence of tumor-reactive TILs in ovarian cancer is
low. To evaluate whether TILs with specific tumor
reactivity are maintained in aAPC expanded cultures,
we selected TILs isolated and expanded in IL-2 from
melanoma fragments, where tumor antigen-specific T
cells are frequently detected for expansion with KT64/
BBL aAPCs (Figure 4a). More than a 220-fold expan-
sion was observed over 10-12 days culture in indepen-
dent assays. MART-1:27-35 peptide-specific CD8+
TILs from HLA-A2+ patients, which were readily
detected in pretreatment TILs, were also observed
Ye et al. Journal of Translational Medicine 2011, 9:131
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Page 7 of 13post-expanded TIL populations (Figure 4b). Control
HER2:369-377 tetramer staining was negative in these
melanoma TIL cultures. In co-culture assays, aAPC-
expanded TILs containing MART-1-specific CD8+ T
cells retained the ability to recognize and respond to
the HLA-matched, MART-1 expressing melanoma
cells line 624, but not when stimulated with HLA-
A2
neg MART-1
+ melanoma (938), or HLA-matched
MART-1
neg (OVCAR5) or HLA-A2
neg MART-1
neg
(SKOV3) ovarian cancer cell lines (Figure 4c), indicat-
ing maintenance of anti-tumor reactivity by aAPC
expanded TILs.
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Page 8 of 13Direct expansion of TILs from fresh digested tumor
specimens
Extended culture of human T cells results in progressive
T cell differentiation and loss of replicative potential
which impairs in vivo T cell persistence and anti-tumor
responses following adoptive cell transfer [20,24,25,38].
We therefore tested whether so-called “young” TILs
could be generated via direct aAPC-based expansion of
TILs. We modified the approach of TIL generation,
using primary co-cultures of collagenase-digested tumor
specimens rather than IL-2 outgrown microcultures
derived from solid tumor fragments. Following enzy-
matic digestion, tumor specimens were comprised of
EpCAM+ tumors cells, and a CD45+ leukocyte popula-
tion that contained CD14+ monocytes and CD3+ T
cells, as well as a CD14- CD3- leukocyte subset (Figure
5a). The frequency of CD3+ T cells in the starting
digested tumor specimens was low, ranging from 0.76%
to 15.68% of all viable cells (mean 6.3 ± 2.1%, n = 7).
Stimulation of 1 million total cells from tumor digested
products with an equivalent number of irradiated aAPC
loaded with anti-CD3/28 antibodies in media supple-
mented with IL-2 yielded on average a 75-fold numeri-
cal expansion of total cells after 11 days, which was
substantially higher than that achieved by IL-2 culture
alone (mean of 5.6-fold; Figure 5b). Stimulation of the
heterogenous tumor cell product resulted in the rapid,
preferential expansion of CD3+ CD45+ T cells, which
dominated the final cell product (Figure 5a). CD64+
CD137+ aAPCs were not detectable in the final TIL
preparation and no viable aAPCs were observed in
independent parallel cultures of aAPC alone after day
six. Longitudinal enumeration of CD3+ TILs during
expansion revealed that TILs, which were a relatively
small portion of the starting digested tumor cell pro-
duct, underwent a robust 1,500-fold mean expansion
over 11 days in culture (Figure 5c). “Young” TILs that
expanded to modest levels (185-fold mean expansion)
were also amenable to secondary expansion with KT64/
BBL aAPC, reaching an average total level of ~25,000-
fold expansion 8 days after restimulation (Additional file
4Figure S4). Phenotypic analysis revealed that “young”
TILs that had been expanded directly from solid tumor
digests with aAPC trended toward having increased
CD8+ T lymphocyte composition (Figure 5d), a higher
frequency of T cells expressing the costimulatory mole-
cules CD27 and CD28 (Figure 5e,f), and reduced fre-
quencies of CD4+ T cells expressing FOXP3, relative to
TILs cultured in IL-2 in parallel (Figure 5g), although
not to the level of statistical significance. Young ovarian
TILs that had been expanded directly from fresh
enzyme-digested tumor specimens exhibited autologous
tumor reactivity ex vivo (IFN-g secretion >200 pg/mL
and twice background) that was statistically similar to
the reactivity of TILs that had been outgrown in parallel
IL-2 cultures (p = 0.95; n = 4; Figure 5h). Reactivity to
MHC-mismatched ovarian cancer cell lines was not
observed (not shown) Thus, TILs can be vigorously
expanded directly from enzyme-digested tumor speci-
mens ex vivo with KT64/BBL aAPCs, and display favor-
able phenotypic and functional attributes for the
application of adoptive immunotherapy of cancer.
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A0201 tetramers. Viable CD3+ T cell gating was performed. (c) aAPC expanded melanoma TILs retain HLA-restricted tumor reactivity in a
standard co-culture and cytokine detection assay. 10
5 aAPC-expanded TILs were co-cultured with 10
5 624 (A2+ MART-1+) or 938 (A2- MART-1+)
melanoma cells, or OVCAR5 (A2+ MART-1-) or SKOV3 (A2- MART-1-) ovarian cancer cells. After overnight culture, supernatants were measured for
secreted IFN-g.
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TIL-based therapy for cancer has shown significant pro-
mise in the clinic [5-7,35,39,40] but TIL expansion pro-
cedures require significant simplification to allow for
wider application, improved cell product development
and better patient outcomes. The results of this study
demonstrate the novel applicability of a more efficient
cellular aAPC-based platform for expansion of human T
lymphocytes derived from solid tumor explants than has
previously been reported. The engineered KT64/BBL
aAPC line evaluated in this study represents an attrac-
tive “off-the-shelf” platform for ex vivo TIL expansion
since aAPC (i) can be grown to large number and cryo-
preserved for the establishment of master and working
cell banks, thus meeting the needs of even the largest
cell cultures, (ii) reduce sample variability, preparative
time requirements and regulatory issues that surround
the use of donor PBMCs as a feeder cell source, (iii) are
amenable to further genetic engineering or antibody
loading to broaden or fine-tune the spectrum of costi-
mulatory or adhesion molecules expressed, (iv) lack
endogenous MHC expression thus eliminating issues of
HLA-compatibility, and (v) alleviate possible infectious
agent concerns related to the use of donor PBMC as
feeder cells.
TILs, which generally express lower levels of CD28
than blood-derived T cells, efficiently expand using
aAPCs in a CD28 independent manner, but require the
addition of exogenous IL-2, likely due to the inability to
TILs to produce their own IL-2 when stimulated with
or with or without CD28 costimulation. The level of
TIL expansion achieved using aAPC is similar to that
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6
total tumor digest cells were stimulated with 10
6 aAPC loaded with anti-CD3 and anti-CD28 agonist antibody in CM containing 100 IU/mL IL-2,
or cultured in 600 IU/mL IL-2 alone. Mean viable cell counts ± SEM are shown (n = 7). (c) Fold expansion of CD3+ TILs. Calculated viable
absolute T cell numbers are shown (Total T cell number times % viable CD3+). (d) Ratio of CD4 + TILs to CD8+ TILs pre- and post-expansion
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enzyme-digested tumor specimens using KT64/BBL aAPC demonstrated autologous tumor reactivity. 10
5 aAPC-expanded TILs or 10
5 TILs
outgrown in 600 IU/mL of IL-2 were co-cultured overnight with 10
5 autologous tumor cells or not stimulated (none). Anti-CD3/28 bead
stimulation was applied as positive control. Mean concentration of IFN-g (pg/mL ± SEM) detected in supernatants from paired aAPC- and IL-2-
expanded TIL cultures from 4 independent ovarian cancer specimens with anti-tumor reactivity is shown.
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Page 10 of 13attained by the REM, adapted from Riddell [8,9], and far
exceeds that of continued culturing in IL-2 or stimula-
tion with beads coated with anti-CD3 and anti-CD28
mAb. The expansion levels reached over 9-11 days of
culture using REM and aAPC as performed here in
small-scale using extended IL-2 cultured ovarian TILs is
less than those levels achieved elsewhere with melanoma
TILs over 14 days by REM [9]. These differences may be
a reflection of dissimilar culture duration, scale, feeder
cell capacity or tumor type. Compared to the 200:1 fee-
der to TIL ratio and 6000 IU/mL IL-2 used for the
REM, stimulation of TILs with aAPCs at a 2:1 ratio and
100 IU/mL IL-2 efficiently expand TILs. More so,
aAPC-expanded cells remain sensitive to secondary
aAPC-based re-stimulation, allowing for a nearly 10,000-
fold total cell expansion. aAPC-expanded TILs are
skewed in CD8+ T cell contribution with few FOXP3+
cells among the smaller CD4+ T cell population, which
may benefit adoptive cell transfer protocols [41,42].
Importantly, the aAPC platform supports the numerical
expansion of tumor antigen-specific T cells within the
TIL population. This likely reflects the use of TIL cul-
tures established from tumor fragments or digests over
3-4 weeks in IL-2, which has been shown to promote
TIL differentiation, telomere shortening and senescence
[25].
Adoptive transfer of TILs possessing properties of less
differentiated T cells, such as high surface expression of
the costimulatory molecules CD28 and CD27 and long
telomeres (>5 kb), is associated with their increased per-
sistence in vivo and correlates with objective cancer
regression [18,20,22-24]. Modification of TIL culture
conditions, including shortening the duration of culture,
use of alternative common g-chain signaling cytokines
and cytokine concentration [25,43,44], can skew TIL dif-
ferentiation status in vitro and improve their in vivo
potency. Alternatively, enrichment for particular T cell
subsets, such as cytotoxic CD8+ T cells, may improve
overall TIL potency and function [42]. We demonstrate
that TILs stimulated with aAPCs directly from fresh
tumor digests undergo more robust expansion, have
increased CD8+ T cell composition, contain a greater
numbers of cells expressing CD28 and CD27, and have
similar function compared to parallel TILs developed
under continuous IL-2 culture conditions. Under aAPC
conditions, TILs selectively expand in culture, while
tumor cells do not. Recent attempts at generating
“young” TILs through minimal cell culture rely upon
short-term (10-18 day) IL-2 incubation followed by
REM expansion of about 14 days [25,35]. Our results
extend upon these findings by demonstrating that even
short term culturing in IL-2 alone can have a negative
impact on overall TIL subset composition and differen-
tiation phenotype. Direct TIL stimulation by aAPC
minimizes overall culture time and the negative effects
of extended in vitro population doubling. Minimized
TIL expansion and culture as described here stands to
reduce overall cell processing time and positively impact
TIL subset and differentiation, which may facilitate
wider application of TIL-based therapy and improve
patient outcome. Based in part on these results, we have
now also established and tested several Master and
Working Cell Banks of K562 aAPCs. Biologics Master
Files have been submitted to the FDA in preparation for
use as ex vivo ancillary reagents in adoptive immu-
notherapy clinical trials.
Conclusion
In this study, we show that cell-based aAPCs represent a
stand-alone, standardized platform for rapid and effi-
cient ex vivo expansion of tumor-infiltrating lympho-
cytes of sufficient number and quality for use in
adoptive immunotherapy. aAPCs can be used to expand
long-term, IL-2 cultured TIL cultures as well as generate
less differentiated “young” TIL cultures with tumor-
reactivity via direct expansion from enzyme-digested
tumors. We conclude that aAPCs overcome costly tech-
nical, regulatory, and logistic challenges of allogeneic
feeder cells, establishing aAPCs a preferable, standar-
dized methodology for the rapid, clinical-grade expan-
sion of TILs for therapy.
Additional material
Additional file 1: Additional Figure S1. Characteristics of KT64/BBL
aAPCs used for TIL expansion. 4-1BBL expression by the aAPC has a
positive impact on TIL expansion potential. KT64/BBL aAPCs were
generated to support the expansion of TILs.( a) aAPCs were
genetically engineered with recombinant lentiviruses to express CD64
and CD137 (4-1BBL; referred to as KT64/BBL) or CD64 alone (KT64).
Engineered cells were isolated by flow-sorting. Enriched KT64/BBL cells
expressed high levels of CD64 and CD137L whereas KT64 expressed high
levels of CD64 but not CD137L, as measured by flow cytometry. Specific
antibodies are shown in gray; isotype antibody control is shown in black.
(b) TIL expansion is augmented by CD137L stimulation. KT64/BBL aAPC
pulsed with anti-CD3 antibody (0.5 ug/10
6 cells) and anti-CD28 antibody
(0.5 ug/10
6 cells) stimulated enhanced TIL expansion at a 2:1 aAPC to T
cell ratio in the presence of exogenous IL-2 (100 IU/ml), compared to
KT64 control aAPC under identical conditions.
Additional file 2: Additional Figure S2. High affinity Fc gamma
receptor CD64 is superior to the low affinity CD32 receptor for TIL
expansion. K562 aAPC engineered to express CD64, but not CD32,
induce rapid TIL expansion. K562 cells engineered to express 4-1BBL
and the low affinity CD32/Fc-gammaRIII (KT32/BBL) or the high affinity
CD64/FcgammaR1 receptor (KT64/BBL) were pulsed with anti-CD3
antibody (0.5 ug/10
6 cells) with or without anti-CD28 antibody (0.5 ug/
10
6 cells) and used to stimulate TIL at a 2:1 aAPC to T cell ratio in the
presence of exogenous IL-2 (100 IU/ml), or cultured in IL-2 containing
medium alone. Representative results from one of three independent
expansions are shown. After a single stimulation at a 2:1 aAPC to T cell
ratio, TILs stimulated with anti-CD3 mAb loaded KT64/BBL aAPCs plus
100 IU/ml IL-2 expanded 100-fold over 9 days. In contrast, TILs did not
undergo robust expansion when stimulated with KT32/BBL aAPCs when
loaded with anti-CD3 mAb (6-fold); with anti-CD3/CD28 mAbs (6-fold); or
with anti-CD3 mAb plus IL-2 (20-fold). These results show that robust TIL
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Page 11 of 13expansion is supported by single-round aAPC and IL-2 stimulation when
the aAPCs express the high affinity Fc receptor CD64, but not CD32.
Additional file 3: Additional Figure S3. PBLs and TILs from ovarian
cancer patients have dissimilar differentiation phenotypes. TILs express
lower levels of CD28 with an effector memory (CD45RO+ CD62L-)
phenotype. TILs outgrown from ovarian cancer specimens in IL-2
display a more differentiated phenotype compared to PBLs.( a)
Peripheral blood T lymphocytes express high levels of CD28 compared
to T cells isolated from an autologous tumor explant. Histograms show
CD28 surface expression by CD3-gated T cells from the blood (grey
filled) or tumor (black filled) of the same patient with ovarian cancer.
Isotype control is shown in empty gray line. (b) TILs outgrown in IL-2
preferentially display an effector memory (CD45RO+ CD62L-) skewed
phenotype, relative to peripheral blood T cells from the same patient
which exhibit diverse differentiation phenotypes including T central
memory (CD45RO+ CD62L+) and naïve (CD45RO- CD62L+) cell
phenotypes
Additional file 4: Additional Figure S4. TILs expanded directly from
enzyme-digested tumors are amenable to secondary expansion using
aAPCs. Young TILs expanded directly from fresh tumor digests are
amenable to secondary expansion using aAPCs.( a)1 0
6 total tumor
digest cells were stimulated with 10
6 aAPC loaded with anti-CD3
antibody with anti-CD28 agonist antibody in CM supplemented with 100
IU/mL IL-2. At day 9 of culture, aAPC stimulated TILs that had undergone
modest primary expansion (185-fold mean) were re-stimulated using
aAPC loaded with anti-CD3 antibody with anti-CD28 agonist antibody in
CM supplemented with 100 IU/mL IL-2 for an additional 8 days. Mean
viable cell ± SD counts are shown relative to day of stimulation (n = 3).
(b) Fold expansion of CD3+ TILs. Pre- and post-expansion cells measured
for contribution of viable CD3+ T cell contribution and used to calculate
absolute T cell numbers (Total T cell number times % viable CD3+).
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